StockNews.AI
GRI
StockNews.AI
19 days

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

1. GRI Bio announced interim data from a Phase 2a study in IPF. 2. The company focuses on therapies using Natural Killer T cell modulators. 3. GRI-0621 aims to treat idiopathic pulmonary fibrosis, addressing unmet medical needs. 4. A robust library of compounds supports GRI Bio's future pipeline developments. 5. CEO Marc Hertz shared insights in a recent virtual investor segment.

3m saved
Insight
Article

FAQ

Why Bullish?

Positive interim biomarker data can enhance investor confidence and attract funding, similar to historical cases such as Gilead Sciences during its developmental phases.

How important is it?

The disclosure of promising clinical data and CEO insights can significantly influence GRI's stock performance by enhancing credibility and interest among investors.

Why Long Term?

The impact of robust Phase 2 data on future trials and commercialization can create sustained investor interest over the long-term.

Related Companies

GILDAMGNVRTX
Access the “What This Means” segment here LA JOLLA, CA, July 31, 2025 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases, today announced that it participated in a Virtual Investor “What This Means” segment. For the segment, Marc Hertz, PhD, President, Chief Executive Officer and Director of GRI, discussed the Company’s recently announced 6-week interim biomarker data from its ongoing Phase 2a study in Idiopathic Pulmonary Fibrosis (“IPF”). The “What This Means” segment can be accessed here. About GRI Bio, Inc. GRI Bio is a clinical-stage biopharmaceutical company focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio’s therapies are designed to target the activity of Natural Killer T (“NKT”) cells, which are key regulators earlier in the inflammatory cascade, to interrupt disease progression and restore the immune system to homeostasis. NKT cells are innate-like T cells that share properties of both NK and T cells and are a functional link between the innate and adaptive immune responses. Type I invariant NKT (“iNKT”) cells play a critical role in propagating the injury, inflammatory response, and fibrosis observed in inflammatory and fibrotic indications. GRI Bio’s lead program, GRI-0621, is an inhibitor of iNKT cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis, a serious disease with significant unmet need. The Company is also developing a pipeline of novel type 2 diverse NKT (“dNKT”) agonists for the treatment of systemic lupus erythematosus. Additionally, with a library of over 500 proprietary compounds, GRI Bio has the ability to fuel a growing pipeline. Investor Contact:JTC Team, LLCJenene Thomas(908) 824-0775GRI@jtcir.com

Related News